5-Year Survival Rates of Non-Small Cell Lung Cancer Patients After Adjuvant Treatment
•Télécharger en tant que PPT, PDF•
288 j'aime•858 vues
This document summarizes a study on the 5-year survival of non-small cell lung cancer patients after adjuvant chemoimmunoradiotherapy compared to surgery alone or postoperative radiotherapy. The study found that adjuvant chemoimmunoradiotherapy significantly improved 5-year survival and lifespan for patients with lymph node metastases (N1-2) compared to the other treatments. However, for patients without lymph node metastases (N0), the 5-year survival was not significantly different between adjuvant chemoimmunoradiotherapy and surgery alone or postoperative radiotherapy.
![Abstract: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (20)
En vedette
Similaire à 5-Year Survival Rates of Non-Small Cell Lung Cancer Patients After Adjuvant Treatment
Similaire à 5-Year Survival Rates of Non-Small Cell Lung Cancer Patients After Adjuvant Treatment (20)
Plus de Oleg Kshivets
Plus de Oleg Kshivets (17)
Dernier
Dernier (20)
5-Year Survival Rates of Non-Small Cell Lung Cancer Patients After Adjuvant Treatment
- 1. 5-Year Survival of Non-Small Cell Lung Cancer Patients after Adjuvant Chemoimmunoradiotherapy Oleg Kshivets, M.D., Ph.D. Department of Surgery, Siauliai Public Hospital, Lithuania The 53 rd Annual Cancer Symposium of Society of Surgical Oncology New Orleans, The USA, 2000
- 7. 5-Year Survivors and Losts
- 8. Results of Factor Analysis
- 9. Results of Factor Analysis
- 10. Nucloids of Lung Cancer Patients with N0-2, n=404
- 11. Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N0-2, n=404
- 12. Nucloids of Lung Cancer Patients with N1-2, n=181
- 13. Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N1-2, n=181
- 14. Network-Model of Lung Cancer Patients with N0-2 (n=404)
- 15. Network-Model of Lung Cancer Patients with N0 (n=223)
- 16. Network-Model of Lung Cancer Patients with N1-2 (n=181)
- 17. Survival of Lung Cancer Patients with N0-2 (n=404)
- 18. Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N0-2, n=404
- 19. Logistic Regression Model of Lung Cancer Patients with N0-2, n=404
- 20. Logistic Regression Model of Lung Cancer Patients with N0-2, n=404
- 21. SEPATH-Model: Clinicopathologic Characteristics-Survival of Lung Cancer Patients with N0-2 metastases (n=404)
- 22. Survival of Lung Cancer Patients with N0-2 (n=404)
- 23. Survival of Lung Cancer Patients with N1-2 (n=181)
- 24. Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N1-2, n=181
- 25. Logistic Regression Model of Lung Cancer Patients with N1-2, n=181
- 26. Logistic Regression Model of Lung Cancer Patients with N1-2, n=181
- 27. SEPATH-Model: Clinicopathologic Characteristics-Survival of Lung Cancer Patients with N1-2 metastases (n=181)
- 28. Results of Monte Carlo Simulation
- 29. Life Span of Died Lung Cancer Patients with N0-2 (n=162)